Treats infections caused by susceptible strains of the designated organisms in the…. ANDA 210662, held by Breckenridge. Tetracycline Hydrochloride.
As of Nov 16, 2026, ANDA 210662 (Tetracycline Hydrochloride), held by Breckenridge, was first approved by FDA on Nov 7, 2018, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 7, 2018 | Original application | Approved | None posted |
| Tetracycline Hydrochloride250MG · capsule;oral | Tetracycline Hydrochloride | Rx |
| Tetracycline Hydrochloride500MG · capsule;oral | Tetracycline Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters